Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate

Journal of Orthopaedic Research

Volumn 30, Issue 5, 2012, Pages 824-830

  Li, Zhaoxu ^a   Peng, Huiqin ^b   Xu, Qiang ^a   Ye, Zhaoming ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

antigen; cytotoxic lymphocytes; gamma delta; immunotherapy; receptors; simple para>Keywords: osteosarcoma; T cell; zoledronic acid

Indexed keywords

NATURAL KILLER CELL RECEPTOR NKG2D; ZOLEDRONIC ACID;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CYTOTOXICITY; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOCYTOTOXICITY; IN VITRO STUDY; MALE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL;

ADOLESCENT; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; MALE; OSTEOSARCOMA; PERFORIN; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; YOUNG ADULT;

EID: 84858277975     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21579     Document Type: Article

References (26)

1. Mirabello L, Troisi RJ, Savage SA,. 2009. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543.
2. Ta HT, Dass CR, Choong PF, et al. 2009. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 28: 247-263.
3. Federman N, Bernthal N, Eilber FC, et al. 2009. The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol 10: 82-93.
4. Ferrari S, Palmerini E, Staals EL, et al. 2010. The treatment of nonmetastatic high grade osteosarcoma of the extremity: review of the Italian rizzoli experience. Impact on the future. Cancer Treat Res 152: 275-287.
5. Jaffe N,. 2010. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 152: 239-262.
6. Theoleyre S, Mori K, Cherrier B, et al. 2005. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer 5: 123.
7. Flutter B, Edwards N, Fallah-Arani, et al. 2010. Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. J Clin Invest 120: 3855-3868.
8. Bouet-Toussaint F, Cabillic F, Toutirais O, et al. 2008. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother 57: 531-539. (Pubitemid 351170536)
9. Beck BH, Kim HG, Kim H, et al. 2010. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. Breast Cancer Res Treat 122: 135-144.
10. Bryant NL, Gillespie GY, Lopez RD, et al. 2011. Preclinical evaluation of ex vivo expanded/activated gammadelta T cells for immunotherapy of glioblastoma multiforme. J Neurooncol 101: 179-188.
11. Nakajima J, Murakawa T, Fukami T, et al. 2010. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 37: 1191-1197.
12. Kobayashi H, Tanaka Y, Shimmura H, et al. 2010. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res 30: 575-579.
13. Lesport E, Baudhuin J, Sousa S, et al. 2011. Inhibition of human Vgamma9Vdelta2 T-cell antitumoral activity through HLA-G: implications for immunotherapy of cancer. Cell Mol Life Sci 68: 3385-3399.
14. Meraviglia S, Caccamo N, Salerno A, et al. 2010. Partial and ineffective activation of V{gamma}9V{delta}2 T cells by Mycobacterium tuberculosis-infected dendritic cells. J Immunol 185: 1770-1776.
15. Labrinidis A, Hay S, Liapis V, et al. 2009. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res 15: 3451-3461.
16. D'Asaro M, La Mendola C, Di Liberto D, et al. 2010. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 184: 3260-3268.
17. Mattarollo SR, Kenna T, Nieda M, et al. 2007. Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer Immunol Immunother 56: 1285-1297. (Pubitemid 46763941)
18. Maletzki C, Linnebacher M, Kreikemeyer B, et al. 2008. Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut 57: 483-491. (Pubitemid 351442532)
19. Todaro M, D'Asaro M, Caccamo N, et al. 2009. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 182: 7287-7296.
20. Moon MH, Jeong JK, Seo JS, et al. 2011. Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp Mol Med 43: 138-145.
21. Kato Y, Tanaka Y, Miyagawa F, et al. 2001. Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol 167: 5092-5098. (Pubitemid 33009743)
22. Muraro M, Mereuta OM, Carraro F, et al. 2007. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. Cell Immunol 249: 63-72.
23. Li Z, Xu Q, Peng H, et al. 2011. IFN-gamma enhances HOS and U2OS cell lines susceptibility to gammadelta T cell-mediated killing through the Fas/Fas ligand pathway. Int Immunopharmacol 11: 496-503.
24. Kubista B, Trieb K, Sevelda F, et al. 2006. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 24: 1145-1152. (Pubitemid 43870876)
25. Clezardin P,. 2011. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. Bone 48: 71-79.
26. Caldwell SA, Ryan MH, McDuffie E, et al. 2003. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J Immunol 171: 2402-2412. (Pubitemid 37025547)